Amarantus Bioscience Holdings Inc (AMBS)

[Voices of Reason]

Unfortunately, the facts do not support the theory of shorters pushing the stock down - this link shows nearly zero activity: http://www.otcmarkets.com/stock/AMBS/short-sales

Holding out hope that a PR firm will somehow rescue this stock slide is simply wishful thinking - irregardless of the validity of their promising technology. The reality check is the following:

Cash on hand = $148
Revenues = $0 (latest quarter)
Costs = $1.4 million (latest quarter)
Liabilities = $3.9 million+
Outstanding shares = 107.4 million

MJFF Grant money left = $0

The selling that you are seeing is most likely related to these series of convertible notes:

Convertible debt = $230k - convertible at 33% of then existing share price (at current price of $0.013, that would equate to roughly 53 million share dilution ) - these series of notes come due starting the end of 2012. This does not include the $41k of convertible note to MMRI for Preferred Stock.

The company states another $500k note to 10 investors which was amended for the note holders to have warrant coverage equal to 100% of the note principal at an exercise price equal to 100% of that to outside investors in the closing of the next equity financing of $1,175,000, but not to be less than $0.60 per share. The warrants expire five years from the date of the next equity financing closing. We are currently in default on these notes.

During the twelve months ended December 31, 2011, the Company issued convertible promissory notes to various investors for aggregate proceeds of $90,000. During the three months ended March 31, 2012, $67,000 of these convertible notes converted to Company Common shares (leaving $23k remaining to be converted).

During the period October, 2011 through March 31, 2012, the Company issued convertible promissory notes to various investors for aggregate proceeds of $168,750.

During the three months ended March 31, 2012, the Company issued two convertible promissory notes to one investor totaling $54,500. Principal and interest on these convertible notes accrue at the rate of 8% per annum.

In January, 2012, a vendor convertible their trade account to convertible promissory notes for the amount due them at the time of the note plus future billings, amounting to $244,988.

The company stil owes Neurotrophics $22k and Dr. Herschkowitz $150k.

Effective November 1, 2011 the Company entered into a consulting agreement where the consultant is to receive a stock option for common stock of 500,000 shares, fully vested.

Notwithstanding the above financial overhang of convertible debt, on January 6, 2012 the Company was served a summons regarding the filing of a lawsuit (Complaint for Breach of Contract, Specific Performance and Common Counts) against the Company by a former consultant to the Company, Peter Freeman v. Amarantus BioSciences, Inc.

In addition the Company is in default on payment of certain Convertible Notes that were due as of December 6, 2011 and is also late with regard to making payments to various trade account vendors for goods and services received, of which some accounts are currently with collection agencies and could possibly result in lawsuits with the Company.

The company also has a stock option plan where over 10.7 million shares can be issued (some of which have already been granted)

The hope that RBCC will somehow provide funding is also wishful thinking.